# TFDP1

## Overview
TFDP1 is a gene that encodes the transcription factor Dp-1, a protein that plays a pivotal role in cell cycle regulation. As a member of the transcription factor family, Dp-1 is characterized by its ability to form heterodimers with E2F transcription factors, which are crucial for the transcriptional activation of genes necessary for DNA replication and cell cycle progression, particularly during the G1/S phase transition (Jibrim2019Expression; Helin1993Heterodimerization). The protein contains a DNA-binding domain and a dimerization domain, facilitating its interaction with E2F proteins and enhancing DNA-binding and transactivation activities (Helin1993Heterodimerization; Bandara1993Functional). TFDP1's involvement in various cellular processes, including its interactions with other proteins and its role in different cancers, underscores its significance in both normal cellular function and disease states (Zhan2017COMMD9; Guo2022KDM6B).

## Structure
The TFDP1 protein, also known as transcription factor Dp-1, is characterized by several structural features that are crucial for its function in cell cycle regulation. The primary structure of TFDP1 consists of a sequence of amino acids that form specific domains essential for its activity. Notably, TFDP1 contains a DNA-binding domain and a dimerization domain, which are critical for its interaction with E2F transcription factors (Helin1993Heterodimerization; Bandara1993Functional).

The secondary structure of TFDP1 includes a winged-helix fold within its DNA-binding domain, which facilitates its ability to bind DNA (Zheng1999Structural). This structural motif is shared among the DP protein family and contributes to the formation of heterodimers with E2F proteins, enhancing DNA-binding and transactivation activities (Zheng1999Structural).

In terms of quaternary structure, TFDP1 forms heterodimers with E2F proteins, which is essential for high-affinity DNA binding and transcriptional regulation. This interaction is stabilized by a hydrophobic heptad repeat that is crucial for dimerization (Helin1993Heterodimerization; Zheng1999Structural).

Post-translational modifications, such as phosphorylation, may affect the activity and stability of TFDP1, although specific modifications are not detailed in the provided context. Splice variant isoforms of TFDP1 may exist, potentially altering its function, but specific variants are not described in the context.

## Function
TFDP1 encodes the DP-1 protein, which plays a crucial role in regulating the cell cycle by forming heterodimers with E2F transcription factors. This complex is essential for the transcriptional activation of genes required for DNA replication and cell cycle progression, particularly during the G1/S phase transition (Jibrim2019Expression; Helin1993Heterodimerization). The E2F/DP-1 heterodimer enhances the binding affinity to E2F DNA-binding sites, leading to cooperative trans-activation of E2F-responsive promoters (Helin1993Heterodimerization).

In healthy human cells, TFDP1 is active in the nucleus, where it influences cell proliferation and differentiation by regulating the expression of genes necessary for S-phase entry, such as DHFR and DNA polymerase alpha (Jibrim2019Expression). The interaction of the E2F/DP-1 complex with the retinoblastoma protein (pRB) is a key regulatory mechanism, as pRB can inhibit the trans-activation activity of the complex, thereby controlling cell growth and preventing uncontrolled proliferation (Helin1993Heterodimerization). This regulation is vital for maintaining normal cell cycle progression and ensuring proper cellular function.

## Clinical Significance
Alterations in the TFDP1 gene, including mutations and changes in expression levels, have been implicated in various diseases and conditions. In hepatocellular carcinomas (HCC), overexpression of TFDP1 is associated with larger tumor sizes and may contribute to tumor progression by promoting cell growth (Yasui2003Association). In breast cancer, TFDP1 overexpression is linked to poor prognosis, including shorter survival and higher tumor aggressiveness, suggesting its role in tumorigenesis (Melchor2009Comprehensive). A case report identified a chromosome 13q34 duplication involving TFDP1, associated with dystonia, facial dysmorphism, intellectual disability, and breast cancer, highlighting the potential clinical significance of TFDP1 overexpression in these conditions (Moscovich2013Dystonia).

In colorectal cancer, a recurrent frame-shift indel mutation in TFDP1, known as indel84, was found in 70% of colorectal cancer tissues. This mutation results in a gain-of-function phenotype, increasing cell proliferation, migration, and invasion, indicating its potential role in cancer progression (Chen2014NextGeneration). In endometriosis, TFDP1 expression is downregulated in the endometrium of affected women, suggesting a link to the disease's pathophysiology (Jibrim2019Expression). These findings underscore the diverse clinical implications of TFDP1 alterations across different diseases.

## Interactions
TFDP1, a transcription factor, is known to form heterodimers with E2F transcription factors, playing a significant role in cell cycle regulation. It interacts with various proteins and nucleic acids, participating in multiple cellular processes. In the context of mouse palatogenesis, TFDP1 interacts with KDM6B to activate Trp53 expression, which is crucial for DNA damage regulation and cell proliferation (Guo2022KDM6B). This interaction involves the removal of the repressive H3K27me3 mark by KDM6B, facilitating TFDP1's binding to the Trp53 promoter (Guo2022KDM6B).

In non-small cell lung cancer, TFDP1 interacts with COMMD9, which enhances TFDP1/E2F1 transcriptional activity. This interaction is mediated by the COMM domain of COMMD9 and the DNA-binding domain of TFDP1, influencing cell cycle progression and cancer development (Zhan2017COMMD9).

In liver cancer, TFDP1 is involved in the nuclear import process mediated by Karyopherin α2 (KPNA2), which is essential for maintaining the expression of the protumorigenic protein stathmin. TFDP1, along with E2F1, binds to the STMN1 promoter, regulating its expression (Drucker2019Karyopherin). These interactions highlight TFDP1's role in various cellular contexts, influencing gene expression and cellular proliferation.


## References


[1. (Drucker2019Karyopherin) Elisabeth Drucker, Kerstin Holzer, Stefan Pusch, Juliane Winkler, Diego F. Calvisi, Eva Eiteneuer, Esther Herpel, Benjamin Goeppert, Stephanie Roessler, Alessandro Ori, Peter Schirmacher, Kai Breuhahn, and Stephan Singer. Karyopherin α2-dependent import of e2f1 and tfdp1 maintains protumorigenic stathmin expression in liver cancer. Cell Communication and Signaling, November 2019. URL: http://dx.doi.org/10.1186/s12964-019-0456-x, doi:10.1186/s12964-019-0456-x. This article has 31 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12964-019-0456-x)

[2. (Zhan2017COMMD9) Weihua Zhan, Wenjuan Wang, Tianyu Han, Caifeng Xie, Tingting Zhang, Mingxi Gan, and Jian-Bin Wang. Commd9 promotes tfdp1/e2f1 transcriptional activity via interaction with tfdp1 in non-small cell lung cancer. Cellular Signalling, 30:59–66, January 2017. URL: http://dx.doi.org/10.1016/j.cellsig.2016.11.016, doi:10.1016/j.cellsig.2016.11.016. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2016.11.016)

[3. (Guo2022KDM6B) Tingwei Guo, Xia Han, Jinzhi He, Jifan Feng, Junjun Jing, Eva Janečková, Jie Lei, Thach-Vu Ho, Jian Xu, and Yang Chai. Kdm6b interacts with tfdp1 to activate p53 signaling in regulating mouse palatogenesis. eLife, February 2022. URL: http://dx.doi.org/10.7554/elife.74595, doi:10.7554/elife.74595. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.74595)

[4. (Helin1993Heterodimerization) K Helin, C L Wu, A R Fattaey, J A Lees, B D Dynlacht, C Ngwu, and E Harlow. Heterodimerization of the transcription factors e2f-1 and dp-1 leads to cooperative trans-activation. Genes &amp; Development, 7(10):1850–1861, October 1993. URL: http://dx.doi.org/10.1101/gad.7.10.1850, doi:10.1101/gad.7.10.1850. This article has 372 citations.](https://doi.org/10.1101/gad.7.10.1850)

[5. (Melchor2009Comprehensive) Lorenzo Melchor, Laura Paula Saucedo-Cuevas, Iván Muñoz-Repeto, Socorro María Rodríguez-Pinilla, Emiliano Honrado, Alfredo Campoverde, Jose Palacios, Katherine L Nathanson, María José García, and Javier Benítez. Comprehensive characterization of the dna amplification at 13q34 in human breast cancer reveals tfdp1 and cul4a as likely candidate target genes. Breast Cancer Research, December 2009. URL: http://dx.doi.org/10.1186/bcr2456, doi:10.1186/bcr2456. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/bcr2456)

[6. (Jibrim2019Expression) Rodrigo Lopes Meime Jibrim, Cristina Valletta de Carvalho, Adriana Luckow Invitti, and Eduardo Schor. Expression of the tfdp1 gene in the endometrium of women with deep infiltrating endometriosis. Gynecological Endocrinology, 35(6):490–493, January 2019. URL: http://dx.doi.org/10.1080/09513590.2018.1540569, doi:10.1080/09513590.2018.1540569. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/09513590.2018.1540569)

[7. (Moscovich2013Dystonia) Mariana Moscovich, Mark S LeDoux, Jianfeng Xiao, Garrett L Rampon, Satya R Vemula, Ramon L Rodriguez, Kelly D Foote, and Michael S Okun. Dystonia, facial dysmorphism, intellectual disability and breast cancer associated with a chromosome 13q34 duplication and overexpression of tfdp1: case report. BMC Medical Genetics, July 2013. URL: http://dx.doi.org/10.1186/1471-2350-14-70, doi:10.1186/1471-2350-14-70. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2350-14-70)

[8. (Chen2014NextGeneration) Chen Chen, Jie Liu, Fan Zhou, Jianbo Sun, Lisha Li, Chengmeng Jin, Jiaofang Shao, Huawei Jiang, Na Zhao, Shu Zheng, and Biaoyang Lin. Next-generation sequencing of colorectal cancers in chinese: identification of a recurrent frame-shift and gain-of-function indel mutation in thetfdp1gene. OMICS: A Journal of Integrative Biology, 18(10):625–635, October 2014. URL: http://dx.doi.org/10.1089/omi.2014.0058, doi:10.1089/omi.2014.0058. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1089/omi.2014.0058)

[9. (Yasui2003Association) Kohichiroh Yasui, Hiroyuki Okamoto, Shigeki Arii, and Johji Inazawa. Association of over-expressed tfdp1 with progression of hepatocellular carcinomas. Journal of Human Genetics, 48(12):609–613, November 2003. URL: http://dx.doi.org/10.1007/s10038-003-0086-3, doi:10.1007/s10038-003-0086-3. This article has 48 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10038-003-0086-3)

[10. (Zheng1999Structural) N. Zheng, E. Fraenkel, C. O. Pabo, and N. P. Pavletich. Structural basis of dna recognition by the heterodimeric cell cycle transcription factor e2f-dp. Genes &amp; Development, 13(6):666–674, March 1999. URL: http://dx.doi.org/10.1101/gad.13.6.666, doi:10.1101/gad.13.6.666. This article has 212 citations.](https://doi.org/10.1101/gad.13.6.666)

[11. (Bandara1993Functional) L.R. Bandara, V.M. Buck, M. Zamanian, L.H. Johnston, and N.B. La Thangue. Functional synergy between dp-1 and e2f-1 in the cell cycle-regulating transcription factor drtf1/e2f. The EMBO Journal, 12(11):4317–4324, November 1993. URL: http://dx.doi.org/10.1002/j.1460-2075.1993.tb06116.x, doi:10.1002/j.1460-2075.1993.tb06116.x. This article has 187 citations.](https://doi.org/10.1002/j.1460-2075.1993.tb06116.x)